Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer

被引：25

作者：

Eichholz, Andrew ^{[1
]}

Ferraldeschi, Roberta ^{[1
]}

Attard, Gerhardt ^{[1
]}

de Bono, Johann S. ^{[1
]}

机构：

[1] Inst Canc Res, Male Urol Canc Res Ctr, Sutton SM2 5NG, Surrey, England

来源：

MOLECULAR AND CELLULAR ENDOCRINOLOGY | 2012年 / 360卷 / 1-2期

关键词：

Abiraterone; Orteronel (TAK-700); VN/124-1 (TOK-001); MDV3100; Heat shock proteins; OGX-427; ABIRATERONE ACETATE; ANTIANDROGEN WITHDRAWAL; PROTEIN EXPRESSION; ANTITUMOR-ACTIVITY; PLUS PREDNISONE; INHIBITOR; GENE; DOCETAXEL; THERAPY; TRIAL;

D O I：

10.1016/j.mce.2011.09.038

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Patients with advanced prostate cancer initially respond very well to medical or surgical castration. Despite a good initial response, the disease progresses to a castration-resistant state. Castration-resistant prostate cancer (CRPC) remains addicted to androgen receptor signaling. The addition of conventional anti-androgen agents, such as bicalutamide, only provides a transient benefit. This has led to a search for further drug targets. Cytochrome P450 17 (CYP17) is an enzyme that is vital for the adrenal biosynthesis of androgens. The CYP17 inhibitor abiraterone acetate has a proven benefit in a phase III randomized trial and other CYP17 inhibitors are currently being evaluated. The novel antiandrogen MDV3100 is a small molecule androgen receptor antagonist with promising activity. Heat shock proteins (HSPs) bind to the androgen receptor and modify its activity. Several HSP inhibitors are under evaluation in clinical trials. This review explores the role of CYP17 inhibitors, MDV3100, and HSP inhibitors. (C) 2011 Elsevier Ireland Ltd. All rights reserved.

引用

页码：68 / 75

页数：8

共 69 条

[31] Recent advances in androgen receptor action [J].

Lee, HJ ;

Chang, C .

CELLULAR AND MOLECULAR LIFE SCIENCES, 2003, 60 (08) :1613-1622

[32]

Linja MJ, 2001, CANCER RES, V61, P3550

[33] Targeting HSP90 for cancer therapy [J].

Mahalingam, D. ;

Swords, R. ;

Carew, J. S. ;

Nawrocki, S. T. ;

Bhalla, K. ;

Giles, F. J. .

BRITISH JOURNAL OF CANCER, 2009, 100 (10) :1523-1529

[34] Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin [J].

Maloney, Alison ;

Clarke, Paul A. ;

Naaby-Hansen, Soren ;

Stein, Rob ;

Koopman, Jens-Oliver ;

Akpan, Akunna ;

Yang, Alice ;

Zvelebil, Marketa ;

Cramer, Rainer ;

Stimson, Lindsay ;

Aherne, Wynne ;

Banerji, Udai ;

Judson, Ian ;

Sharp, Swee ;

Powers, Marissa ;

deBilly, Emmanuel ;

Salmons, Joanne ;

Walton, Michael ;

Burlingame, Al ;

Waterfield, Michael ;

Workman, Paul .

CANCER RESEARCH, 2007, 67 (07) :3239-3253

[35] C17,20-lyase inhibitors.: Part 2:: Design, synthesis and structure-activity relationships of (2-naphthylmethyl)-1H-imidazoles as novel C17,20-lyase inhibitors [J].

Matsunaga, N ;

Kaku, T ;

Ojida, A ;

Tanaka, T ;

Hara, T ;

Yamaoka, M ;

Kusaka, M ;

Tasaka, A .

BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (16) :4313-4336

[36] The androgen axis in recurrent prostate cancer [J].

Mohler, JL ;

Gregory, CW ;

Ford, OH ;

Kim, D ;

Weaver, CM ;

Petrusz, P ;

Wilson, EM ;

French, FS .

CLINICAL CANCER RESEARCH, 2004, 10 (02) :440-448

[37] Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: Therapeutic implications for castration-resistant prostate cancer [J].

Mostaghel, Elahe A. ;

Page, Stephanie T. ;

Lin, Daniel W. ;

Fazli, Ladan ;

Coleman, Ilsa M. ;

True, Lawrence D. ;

Knudsen, Beatrice ;

Hess, David L. ;

Nelson, Colleen C. ;

Matsumoto, Alvin M. ;

Bremner, Witham J. ;

Gleave, Martin E. ;

Nelson, Peter S. .

CANCER RESEARCH, 2007, 67 (10) :5033-5041

[38] The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer [J].

Nishiyama, T ;

Hashimoto, Y ;

Takahashi, K .

CLINICAL CANCER RESEARCH, 2004, 10 (21) :7121-7126

[39] Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer [J].

O'Donnell, A ;

Judson, I ;

Dowsett, M ;

Raynaud, F ;

Dearnaley, D ;

Mason, M ;

Harland, S ;

Robbins, A ;

Halbert, G ;

Nutley, B ;

Jarman, M .

BRITISH JOURNAL OF CANCER, 2004, 90 (12) :2317-2325

[40]

Oh W.K., 2009, 2009 GEN CANC S 2009

← 1 2 3 4 5 6 7 →